School of Medicine

Showing 1-10 of 64 Results

  • Robert Michael Fairchild

    Robert Michael Fairchild

    Clinical Assistant Professor, Medicine - Immunology & Rheumatology

    Bio Dr. Fairchild specializes in the diagnosis, evalaution and management of rheumatologic diseases. He has a particular interest in musculoskeletal ultrasound and heads the Division of Immunology and Rheumatology's Diagnostic and Interventional Musculoskeletal Ultrasound Clinic. Dr. Fairchild, received his Ph.D. from Georgetown University, and his M.D. from Columbia University College of Physicians and Surgeons. He completed internship and residency in the Department of Medicine at Stanford University. He continued on at Stanford, completing his fellowship in rheumatology and subsequently joined the faculty of the Division of Immunology and Rheumatology. He trained in rheumatologic musculoskeletal ultrasound through the USSONAR program and is certified in this technique through the American College of Rheumatology (RhMSUS certification).

  • Alice C. Fan

    Alice C. Fan

    Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Dr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.

  • Diana Farid

    Diana Farid

    Clinical Instructor, Medicine - Vaden Health Center

    Bio Diana Farid MD, MPH is a physician, filmmaker and writer. She is a staff physician at the Stanford Vaden Student Health Center, clinical instructor in the Stanford Department of Medicine, assistant director of Stanford School of Medicine's Program in Bioethics and Film, Medicine and the Muse Program in Medical Humanities and the Arts, Center for Biomedical Ethics. She holds a BA in Peace and Conflict Studies from Berkeley and Masters in Public Health from UCLA where she also completed a Child and Family Health Leadership fellowship focused on health communications. She has provided public health education and health care in rural villages in Honduras, promoted peace in the Ukraine and Malaysia, served at an international school in China, worked at the US Agency for International Development in human rights and has had active roles at both Physicians for Social Responsibility and Physicians for Human Rights. She has cared for patients in a wide range of clinic settings including at the Los Angeles Free Clinic, where she also precepted internal medicine residents. For two years, she served as "Doctoring" course faculty to first year UCLA medical students. She has served as a physician consultant for "The Media Project” as part of Advocates for Youth, where she worked with television and film writers and producers to promote adolescent health through entertainment. As a producer with FiddleHeadFern Productions, she produced her debut feature length documentary film, "American Rhythms" (2009)(, which follows a group of 5th grade students at a Los Angeles urban elementary school and their experience of the positive psychological and emotional health effects of a tailored drumming program.

  • John W. Farquhar, M.D.

    John W. Farquhar, M.D.

    Professor of Medicine and of Health Research and Policy, Emeritus

    Current Research and Scholarly Interests Chronic disease prevention, epidemiology of chronic diseases, community-based education for disease prevention, global health, politics and public health.

  • C. Garrison Fathman

    C. Garrison Fathman

    Professor of Medicine (Immunology and Rheumatology), Emeritus

    Current Research and Scholarly Interests My lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.

  • Mohsen Fathzadeh

    Mohsen Fathzadeh

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio My long-term goal is to learn, develop and design frameworks to implement “Precision Medicine” based on the “rare” and “common” genomic variants. Particularly, I am enthusiastic to construct global precision medicine basis to help individuals with diabetes, insulin resistance and cardiovascular comorbidity.
    After completing my master’s degree in human genetics, I was attracted by the fact that early onset coronary artery disease (CAD) manifest as a genetic subtype of the common type of CAD. In collaboration with Dr. Arya Mani and Dr. Richard Lifton, experts in Mendelian forms of CAD (Yale University), and Dr. Reza Malekzadeh, a pioneer of cohort studies (Tehran University), I contributed to the genetic analysis of families with early onset CAD and metabolic syndrome. We identified DYRK1B as a causative gene (co-first author; N Engl J Med; 2014).
    During my PhD thesis, I worked on exome data of Mendelian/monogenic disorders that have been sequenced at Yale Genome center to filter them for rare and pathogenic variants. Also, I used RNA-Seq to sequence the transcriptome of human skeletal muscle biopsies from the carriers and non-carriers of the DYRK1B mutation. I also applied LFQ-MS (label free quantification- tandem mass spectrometry) to address changes in the proteome of DYRK1B mutants in both human muscle biopsies and in vitro models. Through these studies I gained an experimental and conceptual framework for high-throughput data analyses focusing on the networks of metabolic pathways for insulin resistance.
    After completion of Ph.D. thesis at Yale University, I was enthusiastic to be trained deeply on the genetic basis of diabetes and insulin resistance. Navigating through leading institutes, I found Stanford University an ideal place for this training; because here at Stanford Cardiovascular medicine, Dr. Gerald Reaven, a pioneer of insulin resistance, along with Drs. Thomas Quertermous and Joshua Knowles had developed the multicenter cohort for a GWAS of insulin resistance by direct measures of insulin sensitivity including “clamp-based” measures of insulin resistance. This group had just identified and validated a common SNP (rs1208, 803A>G, K268R) in N-acetyltransferase 2 (NAT2) as insulin resistance variant. In this innovative training and career development, I am taking part in defining the role of Nat1 (mouse ortholog of NAT2) in the global and liver specific knockout mice. We have already profiled ‘OMICs changes in the Nat1 global knockout mice with insulin resistance and extensively analyzed the data with promising finding on possible mechanism of mitochondria substrate availability and cholesterol biosynthesis.
    As we are pursuing the functional genomic studies of human NAT2/mouse Nat1, I wrote a chapter book tilted” The Human Arylamine N-Acetyltransferase Type 2 Gene: Genomics and Cardiometabolic Risk”. To write this chapter book I had the supervision of Dr. Knowles and Dr. David Hein (a pioneer of NAT2 studies in cancer predisposition and pharmacogenetics). This chapter is included in an erudite monograph “Arylamine N-acetyltransferase in Health and Disease”. The link advertising the book published by World Scientific Publishing is:

    During postdoctoral fellowship, I am involved in the joint project of Stanford-Merck on functional characterization of lipodystrophy-like genes identified through GWAS of glycemic traits (fasting insulin, HDL and WHR adjusted for BMI). This study has opened up new possibility and insight to target peripheral adiposity and insulin resistance. We extensively have been studying one of these promising targets in the transgenic mice and in the data from human cohorts. Currently, I am writing the manuscript of these finding and soon we submit it for publication.